DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

National Institutes of Health
National Cancer Institute
Bethesda, Maryland 20205

Building 37, Room 6A0
(301) 496-6007

June 22, 1984

Malcolm A. Martin, M.D.
Chief, Laboratory of
Molecular Microbiology
NIAID
Building 5, Room B1-25

Dear Mal,

I am sorry for the delay in response to your letter of May 14 which I first saw this month because of the Uppsala, Helsinki and Stockholm meetings -- which you may be aware of. After that I had a few commitments here as you know.

I am pleased to send you HTLV-III producing cell lines if you want them but the uninfected HT lines are still being characterized for the first detailed publication on them. Therefore, they are not generally available now. They will be by the end of the summer.

Please let me know your wishes, and I would also appreciate it if you let me know what you plan to do with the uninfected cells. For instance, I do not think it would be appropriate for you to put the French isolate in them. That is for them to do in collaboration with me and my co-workers and is on-going. Perhaps we can do something in collaboration with you. In this regard, there is no one in the biology of retro-viruses I respect more than Janet Hartley and would appreciate her involvement in joint NCI-NIAID studies.

Sincerely yours,

Robert C. Gallo, M.D.

RCG:tas

Attachment
cc: Dr. Janet Hartley
Dr. Peter Fischinger
Dr. Vincent DeVita
Dr. James Wyngaarden

Dr. Martin

Agreement for Receiving H9 or H9/HTLV-IIIB Cell Line

I have read and agree to adhere to the following guidelines for use of H9/HTLV-IIIB:

1. Use of H9 or H9/HTLV-IIIB will be limited to my immediate laboratory. I will not give it out without prior written approval from Dr. Gallo.

2. Work performed will be on a collaborative basis with Dr. Gallo and his laboratory unless stated otherwise.

3. H9 or H9/HTLV-IIIB will not be used for commercial purposes. A U.S. Government (National Cancer Institute) patent is in effect.

4. Use of the H9/HTLV-IIIB line or virus produced from it will be according to U.S. Government recommendations (see attached). Work can be carried out in a biosafety level 2 facility if the equipment, techniques and access to the work area are maintained as biosafety level 3. Large scale production of the virus requires strict biosafety level 3 containment.

5. Any operations using the infected cell outside of biocontainment will be after treatment such as gluteraldehyde fixation.

6. Work with these reagents will not be published without prior approval by Dr. Gallo.

7. Reagents will not be used in comparisons with other viruses.

Signature_____ Date _____

Malcolm A. Martin, M.D.
Chief, Laboratory of
Molecular Microbiology
National Institute of Allergy and
Infectious Diseases
Building 5, Room B1-25
Bethesda, Maryland 20205